Elanco Secures First FDA Conditional Approval for a Dog Treatment Before the Screwworm Fly Even Arrives
As concerns about New World screwworm inch closer to home, Elanco Animal Health has made a move that many veterinarians will see as proactive rather than reactive. The company announced that Credelio QuattroTM-CA1 has received FDA conditional approval for the treatment of infestations caused by New World screwworm larvae in dogs. This marks the first time a companion animal product has earned conditional approval specifically for this parasite.
FDA Renews Canalevia-CA1 for Chemotherapy Induced Diarrhea in Dogs Through 2026
Chemotherapy can be life saving for canine cancer patients, but anyone who has managed a dog with chemotherapy induced diarrhea knows how quickly GI side effects can derail treatment plans, stress pet parents, and drain clinic morale. That is why Jaguar Health’s latest news is worth your attention. The FDA has officially renewed the conditional approval of Canalevia-CA1, extending access to this targeted therapy for chemotherapy induced diarrhea in dogs through December 21, 2026.